Clinical trials: Stage IV, NSCLC
Non-small Cell Lung Cancer
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2)…
- Trial name
- NCT04297605
- Testing
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Carcinoma
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in participants with epidermal growth factor receptor mutation positive (EGFRm+) and mesenchymal epithelial transition…
- Trial name
- SAVANNAH (NCT03778229)
- Testing
- Osimertinib, Savolitinib
- Where
- 90 sites in United States, Brazil and 11 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin is more effective than standard chemotherapy for…
- Trial name
- NCT00004887
- Testing
- carboplatin, cisplatin, ifosfamide
- Where
- United Kingdom
- Sponsor
- The Christie NHS Foundation Trust
Breast Cancer, Lung Cancer
Abraxane and Alimta in Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00470548
- Testing
- Abraxane, Alimta
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, Davis
Lung Cancer
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
The goal of phase 1 of this clinical research study is to find the highest dose of DOTAP:Chol-TUSC2 that can be safely given in combination with Tarceva (erlotinib hydrochloride) to patients with NSCLC.
- Trial name
- NCT01455389
- Testing
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Genprex, Inc.
Lung Cancer Metastatic
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the…
- Trial name
- NCT02976740
- Testing
- SBRT, Immunological Agent, Immunological Factors
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Non Small Cell Lung Cancer
Phase I/II Calcitriol in Lung Cancer
According to the Cancer Atlas, lung cancer remains the major cancer among the 10.9 million new cases of cancer diagnosed annually worldwide.
- Trial name
- NCT00794547
- Testing
- Calcitriol
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Cancer
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006484
- Testing
- carboplatin, paclitaxel, tirapazamine
- Where
- 93 sites in United States
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT07231068
- Testing
- Dositinib mesylate tablets
- Where
- 5 sites in China
- Volunteers
- 153 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
NSCLC Stage IV, NSCLC Stage IIIB
Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study
The purpose of the study is to evaluate the safety and efficacy of two different administration methods of apatinib in NSCLC patients.
- Trial name
- NCT03594682
- Testing
- Intervention/treatment
- Volunteers
- 31 people
- Sponsor
- Beijing Chest Hospital
EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in…
- Conditions
- EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02947386
- Testing
- Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This open-label, multi-center study will evaluate the progression-free survival and safety of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine…
- Trial name
- ESSENCE (NCT01667562)
- Testing
- Erlotinib
- Where
- 4 sites in Serbia
- Volunteers
- 375 people
- Sponsor
- Hoffmann-La Roche
Stage IV NSCLC, NSCLC
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Conditions
- Stage IV NSCLC, NSCLC, Immunotherapy, Fasting Mimicking Diet
- Trial name
- Stage IV NSCLC (NCT06671613)
- Testing
- FMD, Regular Diet Plus FMD
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer
Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer
This trial studies efficacy and safety of combination of vitamin C infusion with modulated electro-hyperthermia (mEHT) in treatment of non small cell lung cancer patients.Phase I of this clinical study is to find the tolerable…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- VCONSCLC (NCT02655913)
- Testing
- vitamin C, Modulated Electro-Hyperthermia (mEHT), Supportive care
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Clifford Hospital, Guangzhou, China
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of autologous dendritic cell-adenovirus CCL21 vaccine (CCL21-gene modified dendritic cell vaccine) combined with intravenous pembrolizumab, and to see how well they work…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03546361
- Testing
- Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous…
- Trial name
- TRITON (NCT06008093)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- 47 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Lung Cancer Non-small Cell Stage IV
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
The third generation epidermal growth factor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Trial name
- NCT04184921
- Testing
- Aspirin 100mg, Osimertinib 80 MG
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non Small Cell Lung Cancer
Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer
Docetaxel and pemetrexed have been validated for previously treated advanced non-small cell lung cancer (NSCLC); however, tolerability is a concern with the docetaxel (tri-weekly 75 mg/m2 schedule).
- Trial name
- NCT01004601
- Testing
- docetaxel, pemetrexed
- Where
- Taiwan
- Volunteers
- 179 people
- Sponsor
- Chang Gung Memorial Hospital
Locally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2
A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2
This study is a multicenter, randomized, open-label, parallel-controlled clinical trial. It is designed to evaluate the efficacy and safety of Befotertinib versus Icotinib as first-line treatment in patients with previously…
- Trial name
- BEST2 (NCT07900243)
- Testing
- Befotertinib, Icotinib
- Volunteers
- 100 people
- Sponsor
- Zhou Chengzhi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.